![](https://webarchive.library.unt.edu/eot2008/20090513102425im_/http://www.cancer.gov/images/spacer.gif) |
![](https://webarchive.library.unt.edu/eot2008/20090513102425im_/http://www.cancer.gov/images/spacer.gif) |
Featured Meetings and Events |
![](https://webarchive.library.unt.edu/eot2008/20090513102425im_/http://www.cancer.gov/images/spacer.gif) |
A calendar of scientific meetings and events sponsored by the National Institutes of Health (NIH) is available at http://calendar.nih.gov.
|
|
Following are newly released NCI research funding opportunities:
Mechanisms of Immune Modulation
Announcement Number: RFA-AT-06-005
Application Receipt Date: Dec. 12, 2006
This funding opportunity will use the R21 award mechanism. For more information, see http://cri.nci.nih.gov/4abst.cfm?initiativeparfa_id=3507. Inquiries: Dr. Young S. Kim - yk47s@nih.gov
Assay Development for High Throughput Molecular Screening
Announcement Number: RFA-RM-07-001
Letter of Intent Receipt Date: Sept. 8, 2006
Application Receipt Date: Sept. 22, 2006
This is a renewal of RFA-RM-06-004 and will use the R21 award mechanism. For more information, see http://cri.nci.nih.gov/4abst.cfm?initiativeparfa_id=3508. Inquiries: Dr. Mark Scheideler - scheidelerm@ninds.nih.gov
For comprehensive information
about NCI funding priorities and opportunities, go to http://www.cancer.gov/researchfunding.
The NIH Roadmap for Medical Research Funding provides a framework of the priorities NIH must address to optimize its research portfolio. It identifies the most compelling opportunities in three main areas: new pathways to discovery, research teams of the future, and re-engineering the clinical research enterprise. For information on additional Roadmap funding opportunities,
go to http://nihroadmap.nih.gov.
|